Skip to main content

Marc D. Cohen

Marc D. Cohen, MD, is Emeritus Professor of Medicine at the Mayo Clinic, Rochester, Minnesota; and Adjunct Professor of Medicine, Division of Rheumatology, at National Jewish Health, Denver, Colorado. Dr. Cohen’s primary interests are rheumatoid arthritis and systemic vasculitis; he is committed to supporting investigations and teaching endeavors that achieve the highest level of quality in medical research and education.

Dr. Cohen is a fellow of the Arthritis and Rheumatism Association and of the American College of Physicians. At the Mayo Clinic, he was named “Teacher of the Year” for eleven consecutive years, and is a recipient of the Mayo Clinic’s Distinguished Educator award. He is the first physician to be included in the Teacher of the Year Hall of Fame at the Mayo Clinic in Jacksonville, Florida, where he was a member of the medical staff  for 22 years. Dr. Cohen has been a lecturer and presenter at meetings and symposia around the world, and is the author of over 60 articles in prestigious journals including Arthritis and Rheumatism, of which he has been advisory editor. Dr. Cohen is an ad hoc reviewer for many medical journals and the author of numerous book chapters and medical education tapes on rheumatology.

Dr. Cohen received his medical degree at George Washington University Medical Center in Washington, DC; completed an internship at Cedars-Sinai Medical Center, Los Angeles, California; and was a resident in internal medicine at the University of California, Los Angeles. He was a fellow in rheumatology at the Mayo Clinic, Rochester, Minnesota.


Latest contributions from Marc D. Cohen


22-03-2018 | Biosimilars | Editorial | Article

Biosimilars: The price is not right

Marc Cohen analyzes the various economic factors influencing the price of biosimilars over recent years in rheumatology, focusing on the United States healthcare system.

Doctor holding pill blister packs

24-10-2017 | Rheumatoid arthritis | Editorial | Article

Demise of the triple

Marc Cohen reviews the use of triple therapy for the treatment of rheumatoid arthritis, and discusses the possible reasons for its underutilization compared with biologic therapies.